Renalytix AI (GB:RENX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix AI, a company at the forefront of AI-enabled kidney disease diagnostics, announced the upcoming admission of a new tranche of shares to the London Stock Exchange’s AIM, with the total number of voting rights in the company set to be 189,933,286 post-admission. This move follows a successful application for additional EIS/VCT qualifying shares, with expectations for further admissions and the commencement of dealings in late October and early November. The company’s issued share capital will reach 333,637,612 Ordinary Shares following the second admission.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.